MEDIUM confidence: 100% data completeness, but the composite (43) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Low explanatory power (R² 0.10) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $844M— | $1.0B+22.9% | $1.8B+76.2% | $2.2B+23.0% | $3.7B+65.2% |
| EPS (dil.) | $-7.20— | $-9.30n/m | $-3.52n/m | $-2.18n/m | $2.33n/m |
| Free Cash Flow | -$718M— | -$613Mn/m | $42Mn/m | -$43M-201.5% | $465Mn/m |
| Gross Margin | 83.4% | 83.7%+0.3pp | 83.0%-0.7pp | 85.6%+2.6pp | 81.8%-3.8pp |
| Operating Margin | -83.9% | -75.7%+8.3pp | -15.4%+60.2pp | -7.9%+7.6pp | 13.5%+21.4pp |
| Net Margin | -101.0% | -109.0%-8.0pp | -24.1%+85.0pp | -12.4%+11.7pp | 8.4%+20.8pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $399 (last qtr, 13 analysts) → $370 (last mo, 8) (-7.4%).
Buy-rated share 73% → 79% over ~3 months (+5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $1.63 | $1.21 | -25.8% |
| Apr 2026 | $0.87 | $1.51 | +73.2% |
| Feb 2026 | $1.16 | $0.82 | -29.3% |
| Oct 2025 | $0.56 | $2.90 | +416.9% |
| Jul 2025 | $-0.54 | $0.32 | +158.9% |
| May 2025 | $-0.89 | $-0.01 | +98.9% |
| Feb 2025 | $-0.62 | $0.06 | +109.7% |
| Oct 2024 | $-0.92 | $-0.50 | +45.5% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$7.4M over 180 days (0 open-market buys, 73 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 18.9%/yr (revenue basis).
Base free cash flow $155M (avg FY2023–FY2025; latest year $465M) · equity value $30.1B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 43 for Alnylam Pharmaceuticals indicates a neutral outlook, with the stock's strong growth prospects offset by concerns around valuation and momentum. The company scores high on growth, driven by impressive revenue and earnings growth, as well as a high ROE near 94%. However, it trades at a premium, with a P/E of 36.8, and exhibits weak momentum, having fallen 47.8% over the past year, contributing to the relatively low overall score, which also shows a notable divergence between long-term and short-term scores.